ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS 2012 Appropriate Use Criteria for Peripheral Vascular Ultrasound and Physiological Testing Part I: Arterial Ultrasound and Physiological Testing A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery by Mohler, Emile R. et al.
Journal of the American College of Cardiology Vol. 60, No. 3, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00APPROPRIATE USE CRITERIA
ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS
2012 Appropriate Use Criteria for Peripheral Vascular
Ultrasound and Physiological Testing Part I:
Arterial Ultrasound and Physiological Testing
A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force,
American College of Radiology, American Institute of Ultrasound in Medicine, American Society of
Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation
of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of
Cardiovascular Computed Tomography, Society for Interventional Radiology, Society for Vascular
Medicine, and Society for Vascular Surgery
Endorsed by the American Academy of Neurology, American Podiatric Medical Association, Society for Clinical
Vascular Surgery, Society for Cardiovascular Magnetic Resonance, and Society for Vascular Ultrasound






Copies: This document is aEmile R. Mohler III, MD, FACC, Chair*
Heather L. Gornik, MD, FACC†
Marie Gerhard-Herman, MD‡
Sanjay Misra, MD, FSIR§
Jeffrey W. Olin, DO, FACC, FAHA¶g/cgi/content/full/j.jacc.2012.02.009.
vailable on the World Wide Web site of the American
of Cardiolog
healthpermiss*American College of Cardiology Foundation Representative; †Society
for Vascular Medicine Representative; ‡American Society of Echocar-
diography; §American College of Radiology Representative; Society
for Interventional Radiology Representative; ¶American Heart Associ-
ation Representative; #Society for Vascular Surgery RepresentativeR. Eugene Zierler, MD#
Technical
Panel
Michael J. Wolk, MD, MACC, Moderator
Emile R. Mohler III, MD, FACC,
Writing Group Liaison
Bradley S. Dixon, MD**
Vickie R. Driver, DPM, MS††
Peter S. Fail, MD, FSCAI‡‡
Reza Fazel, MD, MSc*
Laura Findeiss, MD, FSIR
Richard Fuchs, MD, FACC*
John Gillespie, MD*
Joseph P. Hughes, RVT, RVS, FSVU§§
Cheryl Jaigobin, MD 
Steven A. Leers, MD¶¶
Colleen Moore, MD#
John S. Pellerito, MD, FACR, FAIUM§
Michelle L. Robbin, MD, FACR, FAIUM§
Rita E. Shugart, RN, RVT, FSVU†
Fred A. Weaver, MD, MMM##
Christopher J. White, MD, FSCAI¶†††
Alexander S. Yevzlin, MD**
**American Society of Nephrology Representative; ††American Podi-
atric Medical Association Representative; ‡‡Society of Cardiovascular
Computed Tomography Representative; §§Society for Vascular Ultra-
sound Representative;  American Academy of Neurology Representa-
tive; ¶¶Society for Clinical Vascular Surgery Representative; ##Inter-
societal Commission for the Accreditation of Vascular Laboratories
Representative; ***American Institute of Ultrasound in Medicine Rep-
resentative; †††Society for Cardiovascular Angiography and Interven-
tions Representative
This document was approved by the American College of Cardiology Foundation
Board of Trustees in February 2012.
The American College of Cardiology Foundation requests that this document be cited as
follows: Mohler III ER, Gornik HL, Gerhard-Herman M, Misra S, Olin JW, Zierler RE.
ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS 2012 appropriate
use criteria for peripheral vascular ultrasound and physiological testing part I: arterial ultrasound
and physiological testing. J Am Coll Cardiol 2012;60:242–76.
The Online Appendix and other supplemental material for this article are available
College of Cardiology (www.cardiosource.org). For copies of this document, please
contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail reprints@
elsevier.com.
This article is reprinted in Catheterization and Cardiovascular Interventions, the
Journal for Vascular Ultrasound, the Journal of Cardiovascular Computed Tomography,
the Journal of Vascular Surgery, and Vascular Medicine.
Permissions: Modification, alteration, enhancement, and/or distribution of this
document are not permitted without the express permission of the American Collegey Foundation. Please contact Elsevier’s permission department
ions@elsevier.com.
243JACC Vol. 60, No. 3, 2012 Mohler III et al.
July 17, 2012:242–76 Peripheral Vascular Ultrasound and Physiological Testing Part I: ArterialAppropriate
Use Criteria
Task Force
Michael J. Wolk, MD, MACC, Chair
Steven R. Bailey, MD, FACC, FSCAI,
FAHA
Pamela S. Douglas, MD, MACC, FAHA,
FASE
Robert C. Hendel, MD, FACC, FAHA,
FASNC
Christopher M. Kramer, MD, FACC, FAHA
James K. Min, MD, FACC
Manesh R. Patel, MD, FACC
Leslee Shaw, PhD, FACC, FASNC
Raymond F. Stainback, MD, FACC, FASE
Joseph M. Allen, MATABLE OF CONTENTS
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .244
Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .244
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .244
2. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .245
3. Assumptions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .245
4. Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .247
5. Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .247
6. Peripheral Vascular Ultrasound and Physiological
Testing Appropriate Use Criteria (by Indication) . . . . . . .248
Section 1. Extracranial Cerebrovascular
Ultrasound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .248
Table 1.1. Evaluation for Cerebrovascular
Disease—Potential Signs and/or Symptoms. . . . . . . . . . .248
Table 1.2. Evaluation for Cerebrovascular
Disease—Asymptomatic With Comorbidities or
Risk Factors for Carotid Artery Stenosis. . . . . . . . . . . . . .248
Table 1.3. Follow-Up or Surveillance for
Carotid Artery Stenosis—Asymptomatic. . . . . . . . . . . . . .249
Table 1.4. Surveillance After Carotid Artery
Intervention. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .249
Section 2. Carotid Duplex Screening
Ultrasound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .249
Table 2.1. Limited Screening Study for
Carotid Artery Plaque—Asymptomatic . . . . . . . . . . . . . . .249
Summary: Extracranial Cerebrovascular and
Carotid Duplex Screening Ultrasound . . . . . . . . . . . . . . . . . . . . .250
Section 3. Renal and Mesenteric Artery
Duplex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .251
Table 3.1. Evaluation for Renal Artery
Stenosis—Potential Signs and/or Symptoms . . . . . . . . . .251
Table 3.2. Screening for Renal Artery
Stenosis—Asymptomatic. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .251
Table 3.3. Evaluation for Mesenteric Artery
Stenosis—Potential Signs and/or Symptoms . . . . . . . . . .251
Table 3.4. Follow-Up Testing for Renal Artery
Stenosis—Asymptomatic. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .252
Table 3.5. Surveillance After Renal or
Mesenteric Artery Revascularization . . . . . . . . . . . . . . . . . .252Summary: Renal and Mesenteric Artery Ultrasound . . . . . .252Section 4. Aortic and Aortoiliac Duplex . . . . . . . . . . . . . . . .252
Table 4.1. Evaluation for Abdominal Aortic
Disease—Signs and/or Symptoms . . . . . . . . . . . . . . . . . . . .252
Table 4.2. Screening for Abdominal Aortic
Aneurysm—Asymptomatic. . . . . . . . . . . . . . . . . . . . . . . . . . . .253
Table 4.3. Surveillance of Known Abdominal
Aortic Aneurysm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .253
Table 4.4. Surveillance After Aortic Endograft or
Aortoiliac Stenting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .254
Summary: Aortic and Aortoiliac Artery Duplex . . . . . . . . . . .254
Section 5. Lower Extremity Artery Testing Using
Multilevel Physiological Testing Alone or Duplex
Ultrasound With Single-Level ABI
and PVR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .255
Table 5.1. Evaluation for Lower Extremity
Atherosclerotic Disease—Potential Signs and/or
Symptoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .255
Table 5.2. Surveillance of Known Lower Extremity
PAD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .256
Table 5.3. Surveillance of Lower Extremity
PAD After Revascularization (Duplex/ABI) . . . . . . . . . .256
Section 6. Lower Extremity Artery Testing With
ABI Only. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .256
Table 6.1. Screening for Lower Extremity
Atherosclerotic Disease—Potential Signs . . . . . . . . . . . . .256
Table 6.2. Screening for Lower Extremity
Atherosclerotic Disease—Asymptomatic With
Comorbidities. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .257
Section 7. Lower Extremity Artery Testing With
Duplex Ultrasound Only . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .257
Table 7.1. Evaluation for Groin Complication After
Femoral Access . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .257
Section 8. Upper Extremity Arterial
Testing—Physiological Testing or Duplex Ultrasound
Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .257
Table 8.1. Evaluation for Upper Extremity PAD—Potential
Signs and/or Symptoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .257
Table 8.2. Surveillance of Upper Extremity PAD After
Revascularization. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .258
Summary: Upper and Lower Extremity Artery Testing . . .258
7. Peripheral Vascular Ultrasound and Physiological
Testing Appropriate Use Criteria (by Rating) . . . . . . .259
Table 9. Appropriate Indications
(Median Score 7–9). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .259
Table 10. Uncertain Indications
(Median Score 4–6) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .263
244 Mohler III et al. JACC Vol. 60, No. 3, 2012
Peripheral Vascular Ultrasound and Physiological Testing Part I: Arterial July 17, 2012:242–76Table 11. Inappropriate Indications
(Median Score 1–3). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .267
8. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .270
Summary of Evidence and Call for Additional
Research. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .270
Appendix A: Additional Methods . . . . . . . . . . . . . . . . . . . . . . . . .271
Appendix B: ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/
SCCT/SIR/SVM/SVS 2012 Appropriate Use Criteria for
Peripheral Vascular Ultrasound and Physiological
Testing Part I: Arterial Participants . . . . . . . . . . . . . . . . . . . . . .271
Appendix C: ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/
SCCT/SIR/SVM/SVS 2012 Appropriate Use Criteria for
Peripheral Vascular Ultrasound and Physiological
Testing Part I: Arterial Writing Group, Technical Panel,
Task Force, and Indication Reviewers—Relationships
With Industry and Other Entities (in Alphabetical
Order) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .274
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .275
Abstract
The American College of Cardiology Foundation (ACCF),
in partnership with key specialty and subspecialty societies,
conducted a review of common clinical scenarios where
noninvasive vascular testing (ultrasound and physiological
testing) is frequently considered. The indications (clinical
scenarios) were derived from common applications or an-
ticipated uses, as well as from current clinical practice
guidelines and results of studies examining the implemen-
tation of the original appropriate use criteria (AUC). The
159 indications in this document were developed by a
diverse writing group and scored by a separate independent
technical panel on a scale of 1 to 9, to designate appropriate
use (median 7 to 9), uncertain use (median 4 to 6), and
inappropriate use (median 1 to 3).
A total of 255 indications (with the inclusion of
surveillance timeframes) were rated. One hundred and
seventeen indications were rated as appropriate, 84 were
rated as uncertain, and 54 were rated as inappropriate.
The AUC for peripheral vascular disease have the poten-
tial to impact physician decision making, healthcare
delivery, and reimbursement policy. Furthermore, recog-
nition of uncertain clinical scenarios facilitates identifi-
cation of areas that would benefit from future research.
Preface
In an effort to respond to the need for the rational use of
imaging services in the delivery of high-quality care, the
ACCF has undertaken a process to determine the appro-priate use of cardiovascular imaging for selected patient
indications. AUC publications reflect an ongoing effort by
the ACCF to critically and systematically create, review, and
categorize clinical situations where diagnostic tests and
procedures are utilized by physicians caring for patients with
cardiovascular diseases. The process is based on current
understanding of the technical capabilities of the imaging
modalities examined. Although impossible to be entirely
comprehensive given the wide diversity of clinical disease,
the indications are meant to identify common scenarios
encompassing the majority of situations encountered in
contemporary practice. Given the breadth of information
they convey, the indications do not directly correspond to
the Ninth Revision of the International Classification of
Diseases (ICD-9) system as these codes do not include
clinical information, such as symptom status.
The ACCF believes that careful blending of a broad
range of clinical experiences and available evidence-based
information will help guide a more efficient and equitable
allocation of healthcare resources in cardiovascular imaging.
The ultimate objective of AUC is to improve patient care and
health outcomes in a cost-effective manner, but it is not
intended to ignore ambiguity and nuance intrinsic to clinical
decision making. AUC thus should not be considered substi-
tutes for sound clinical judgment and practice experience.
We are grateful to the technical panel, a professional
group with a wide range of skills and insights, for their
thoughtful and thorough deliberation of the merits of
peripheral vascular ultrasound for various indications. We
would also like to thank the 24 individuals who provided a
careful review of the draft of indications, the parent AUC
Task Force, and the ACC staff, Joseph Allen and Jenissa
Haidari for their exceptionally skilled support in the gener-
ation of this document.
Emile R. Mohler III, MD, FACC
Chair, Peripheral Vascular Ultrasound and Physiological Testing
Michael J. Wolk, MD, MACC
Chair, Appropriate Use Criteria Task Force
1. Introduction
Improvements in cardiovascular imaging technology and
their application, coupled with increasing therapeutic op-
tions for cardiovascular disease, have led to an increase in
cardiovascular imaging. Diagnostic imaging services reim-
bursed under Medicare’s physician fee schedule grew more
rapidly than any other type of physician service from 1999 to
2003, although more recently, the rate of imaging volume
growth in Medicare has been slowing. Still, the armamen-
tarium of noninvasive diagnostic tools has expanded greatly,
offering a variety of new and more sophisticated imaging
techniques. As imaging technology and clinical applications
continue to advance, the healthcare community needs to
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long-standing established imaging technologies. In an effort
to respond to this need and to ensure the effective use of
advanced diagnostic imaging tools, the Appropriate Use
Criteria (AUC) project was initiated.
2. Methods
The indications included in this publication cover a wide
array of cardiovascular signs and symptoms as well as clinical
judgments as to the likelihood of cardiovascular findings.
Within each main disease category, a standardized approach
was used to capture the majority of clinical scenarios
without making the list of indications excessive.
The indications were constructed by experts in peripheral
vascular disease and in other fields and were modified on the
basis of discussions among the task force and feedback from
independent reviewers and the technical panel. Wherever
possible, indications were mapped to relevant clinical guide-
lines and key publications/references where available in the
medical literature (Online Appendix).
A detailed description of the methods used for ranking
the selected clinical indications is found in a previous
publication, “ACCF Proposed Method for Evaluating the
Appropriateness of Cardiovascular Imaging” (1). Briefly,
this process combines evidence-based medicine and practice
experience by engaging a technical panel in a modified
Delphi exercise.
The technical panel first rated indications independently.
Then, the panel was convened for a face-to-face meeting for
discussion of each indication. At this meeting, panel mem-
bers were provided with their scores and a blinded summary
of their peers’ scores. After the meeting, panel members
were then asked to independently provide their final scores
for each indication.
Although panel members were not provided explicit cost
information to help determine their appropriate use ratings,
they were asked to implicitly consider cost as an additional
factor in their evaluation of appropriate use. In rating these
criteria, the technical panel was asked to assess whether the
use of the test for each indication is appropriate, uncertain,
or inappropriate, and was provided the following definition
of appropriate use:
An appropriate imaging study is one in which the expected
incremental information, combined with clinical judgment,
exceeds the expected negative consequence* by a sufficiently
wide margin for a specific indication that the procedure is
generally considered acceptable care and a reasonable ap-
proach for the indication.
*Negative consequences include the risks of the procedure (i.e., radiation or contrast
exposure) and the downstream impact of poor test performance such as delay in
diagnosis (false negatives) or inappropriate diagnosis (false positives).The technical panel scored each indication as follows:
Median Score 7 to 9
Appropriate test for specific indication (test is generally
acceptable and is a reasonable approach for the indication).
Median Score 4 to 6
Uncertain for specific indication (test may be generally accept-
ble and may be a reasonable approach for the indication).
ncertainty also implies that more research and/or patient infor-
ation is needed to classify the indication definitively.
Median Score 1 to 3
Inappropriate test for that indication (test is not generally
cceptable and is not a reasonable approach for the indication).
The division of these scores into 3 levels of appropriate-
ness is somewhat arbitrary, and the numeric designations
should be viewed as a continuum. Further, there is diversity
in clinical opinion for particular clinical scenarios, such that
scores in the intermediate level of appropriate use should be
labeled “uncertain,” as critical patient or research data may
be lacking or discordant. This designation should be a
prompt to the field to carry out definitive research investi-
gations whenever possible. It is anticipated that the AUC
reports will continue to be revised as further data are
generated and information from the implementation of the
criteria is accumulated.
To prevent bias in the scoring process, the technical panel
was deliberately comprised of a minority of specialists in
vascular noninvasive testing. Specialists, although offering im-
portant clinical and technical insights, might have a natural
tendency to rate the indications within their specialty as more
appropriate than nonspecialists (1). In addition, care was taken
in providing objective, nonbiased information, including
guidelines and key references, to the technical panel.
The level of agreement among panelists as defined by
RAND (2) was analyzed based on the BIOMED rule for a
panel of 14 to 16 members. As such, agreement was defined
as an indication where 4 or fewer panelists’ ratings fell
outside the 3-point region containing the median score.
Disagreement was defined as where at least 5 panelists’
ratings fell in both the appropriate and the inappropriate
categories. Any indication having disagreement was catego-
rized as uncertain regardless of the final median score.
Indications that met neither definition for agreement or
disagreement are in a third, unlabeled category.
3. Assumptions
To prevent any inconsistencies in interpretation, specific
assumptions are provided that were considered by the
technical panel in rating the relevant clinical indications for
the appropriate use of peripheral vascular ultrasound and
physiological testing.
A peripheral vascular ultrasound and physiological testing
examination and report will include:
1. Performance of the vascular ultrasound or physiological
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color flow and spectral Doppler waveform images as
required for the specific test type. Scanning protocols
may be developed by the laboratory based upon
laboratory-specific considerations and techniques as
well as recommended technical elements per appropri-
ate organizations (e.g., American Institute of Ultra-
sound in Medicine, Society of Vascular Ultrasound)
or laboratory accrediting organizations (Intersocietal
Commission for the Accreditation of Vascular Labora-
tories, ICAVL, or American College of Radiology,
ACR) (3).
2. Interpretation of the vascular ultrasound or physiolog-
ical testing examination by a physician interpreter using
standard, laboratory specific diagnostic criteria that
have been developed by the laboratory or adapted from
the ultrasound literature and are validated internally for
accuracy as part of ongoing quality assurance programs.
It is implicit that diagnostic criteria will vary across
laboratories, but adherence to pre-defined criteria
within a laboratory is required. Laboratory-specific
protocols should be compiled in written policy and
procedure manuals that are made available to medical
and technical staff for review and discussion.
3. Appropriate equipment is used for each specific type of
testing, including appropriate frequency ultrasound
transducers and appropriately sized cuffs for physiolog-
ical testing.
4. Documentation that the vascular sonographer used
optimal angle correction techniques to ensure accurate
angle of insonation for reporting of Doppler velocity
measurements. In general, an angle of insonation of 60
degrees or less is used with appropriate sample volume
placement.
5. All standard vascular ultrasound and physiological test-
ing techniques have a sensitivity and specificity similar
to those found in the published literature for the
specific examination type.
6. Testing should be performed by a credentialed technol-
ogist (RVT or RVS) and interpreted by a credentialed
physician (RPVI or ACR). Finally, the testing should
be done in an accredited facility (ICAVL or ACR).
7. If prior testing is of poor technical quality, repeat
imaging may sometimes be appropriate in a different
facility or after the conditions that restricted the prior
testing are no longer present (e.g., bowel gas, open
wounds) prior to the specified timeframes.
8. The appropriate use of testing is assumed to have the
potential to impact clinical decision making and to
direct therapeutic interventions.
9. The range of potential indications for vascular ultra-
sound and physiological testing is quite large, particu-
larly in comparison with other cardiovascular imaging
tests. Thus, the indications are, at times, purposefully
broad to cover an array of vascular signs and symptoms
as well as the ordering physician’s best judgment as tothe presence of vascular abnormalities. Additionally,
there are likely clinical scenarios that are not covered by
the current indications in this document.
0. For all stress physiological testing, the mode of stress
testing is assumed to be exercise for patients able to
exercise. Laboratory-specific protocols should specify
the precise form of exercise protocol used (e.g., tread-
mill walking exercise protocol indicating speed and
grade of treadmill settings and the specifics of other
forms of exercise testing).
1. Complete vascular examinations, vascular ultrasound
and physiological testing, require bilateral studies in the
majority of clinical cases (such as carotid duplex exam-
ination, renal duplex examination, lower extremity
physiologic testing), unless specific clinical indications
warrant a limited study (e.g., surveillance following
unilateral lower extremity revascularization).
2. Carotid duplex ultrasound refers to testing protocols for
evaluation of the extracranial cerebrovasculature only
and does not include transcranial Doppler or transcra-
nial duplex examinations.
3. To optimize patient care and minimize need for un-
necessary repeat studies, it is generally recommended
that repeat or serial scans (e.g., for surveillance of
asymptomatic carotid artery stenosis) be performed in
the same facility.
4. Raters were instructed to consider cost implicitly when
making the appropriate use determination.
5. Raters were instructed to consider patient safety implic-
itly in the appropriate use determination.
6. If the reason for a test can be assigned to more than 1
clinical indication, it should be matched to the indica-
tion with the highest appropriate use score.
7. For each indication, the rating should reflect whether
the test is reasonable for the patient according to the
appropriate use definition, not whether the test is the
better or worse than another.
8. The category of “uncertain” should be used when insuffi-
cient clinical data are available for a definitive categoriza-
tion or when there is disagreement as defined in the
Methods section. The designation of “uncertain” is assumed
to not provide grounds for denial of reimbursement.
9. When multiple timeframes are presented for surveil-
lance examinations within the indications, the shortest
timeframe scored as either uncertain or appropriate
marks the start of the period during which testing may
be considered reasonable. It is important that clinical
judgment be used during the period in which surveil-
lance is considered either uncertain or appropriate to
determine the optimal time of surveillance.
0. Unless explicitly stated, the indications in this docu-
ment indicate only whether vascular ultrasound or
physiological testing by itself is reasonable. The indi-
cations do not address whether it is reasonable to
perform vascular ultrasound or physiological testing
22
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before or after the test.
1. Surveillance indications require consideration of several
timeframes. Unlike other indications, the rater should
consider the comparative utility of surveillance at the
various frequencies specified.
2. New or worsening symptoms during a surveillance
period should be considered similar to the initial pre-
sentation and assumed to be covered by the earlier
relevant indications rather than the surveillance tables.
4. Definitions
1. Claudication:
Reproducible muscle discomfort or fatigue occurring
with exertion at the same workload and relieved with
rest, typically due to arterial obstruction.
2. Cold extremity:
Reduced temperature from patient history or observed
on physical examination by physician.
3. Physiological testing:
Evaluation of the peripheral circulation based on measure-
ment of limb blood pressures with pulse volume recordings
or Doppler waveforms, or other parameters without utiliz-
ing data from direct imaging of the blood vessels.
4. Resistant hypertension:
The failure to normalize blood pressure on 3 or more
drug regimen with medications at maximum doses and at
least 1 of the medications being a diuretic agent.5. Malignant hypertension:
Uncontrolled hypertension causing acute heart failure,
acute renal failure, or acute visual or mental status
changes.
6. Disease surveillance:
Baseline physiological testing or imaging:
Testing conducted for initial diagnosis or for initial clinical
evaluation post surgical or percutaneous intervention.
Surveillance:
Physiological testing or imaging conducted to monitor
disease progression based solely on the passage of time
since initial diagnosis or revascularization. It is assumed
that baseline testing has already been conducted.
5. Abbreviations
ABI  ankle-brachial index
ACE  angiotensin-converting enzyme inhibitor
ARB  angiotensin II receptor blocker
CABG  coronary artery bypass graft
CT  computed tomography
GI  gastrointestinal
ICA  internal carotid artery
ICAVL  Intersocietal Commission for the Accreditation
of Vascular Laboratories
IMT  intima-media thickness
PAD  peripheral artery disease
PVR  pulse volume recording
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Section 1. Extracranial Cerebrovascular Ultrasound




1. ● New or worsening hemispheric neurological symptoms (e.g., unilateral motor or sensory deficit, speech impairment, or
amaurosis fugax)
● Evaluation of transient ischemic attack or stroke
A (9)
2. ● Hollenhorst plaque visualized on retinal examination A (8)
3. ● Lightheadedness or impaired vision in the setting of upper extremity exertion
● Evaluation for subclavian–vertebral steal phenomenon
A (7)
4. ● Syncope of uncertain cause after initial cardiovascular evaluation U (5)
5. ● Suspected symptomatic vertebrobasilar occlusive disease in the symptomatic patient (e.g., vertigo, ataxia, diplopia,
dysphagia, dysarthria)
A (7)
6. ● Evaluation for suspected carotid artery dissection A (8)
7. ● Pulsatile neck mass A (8)
8. ● Cervical bruit
● No prior carotid artery assessment
A (7)
A  appropriate; I  inappropriate; U  uncertain.




9. ● No cervical bruit
● Atherosclerotic disease in other vascular beds (e.g., lower extremity PAD, coronary artery disease,
abdominal aortic aneurysm)
A (7)
10. ● No cervical bruit
● History of neck irradiation 10 years ago
U (5)
11. ● Known renal fibromuscular dysplasia U (5)
Prior to Open Heart Surgery
12. ● Planned coronary artery bypass grafting (CABG) U (6)
13. ● Atherosclerotic disease in other vascular beds (e.g., lower extremity PAD, coronary artery disease,
abdominal aortic aneurysm), or history of neck irradiation 10 years ago
● Planned valve repair/replacement surgery (without CABG)
U (6)
14. ● Atherosclerotic risk factors present
● Planned valve repair/replacement surgery (without CABG)
U (6)
15. ● No atherosclerotic risk factors
● Planned valve repair/replacement surgery (without CABG)
U (4)
A  appropriate; CABG  coronary artery bypass graft; I  inappropriate; PAD  peripheral artery disease; U  uncertain.
urement of carotid intimal medial thickness.
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Table 1.3. Follow-Up or Surveillance for Carotid Artery Stenosis
Indication
16. ● Normal prior examination (no plaque, no stenosis)
Surveillance Frequency During First Year
17. ● Plaque without significant stenosis of the ICA (plaque, normal IC
18. ● Mild ICA stenosis (e.g., 50%)
19. ● Moderate ICA stenosis (e.g., 50% to 69%)
20. ● Severe ICA stenosis (e.g., 70% to 99%)
Surveillance Frequency After First Year
21. ● Plaque without significant stenosis of the ICA (plaque, normal IC
22. ● Mild ICA stenosis (e.g., 50%)
23. ● Moderate ICA stenosis (e.g., 50% to 69%)
24. ● Severe ICA stenosis (e.g., 70% to 99%)
*In the setting of interval development of clinical symptoms in a previously asymptomatic patient
a limited period of time), more intensive surveillance may be indicated. †Carotid artery occlusion t
according to the severity of stenosis of the contralateral side.
A  appropriate; I  inappropriate; ICA  internal carotid artery; U  uncertain.
Table 1.4. Surveillance After Carotid Artery Intervention
Indication
25. ● Baseline (within 1 month) after carotid intervention
Asymptomatic or Stable Symptoms After Baselin
Surveillance Frequency During First Year
26. ● Following normal ipsilateral ICA baseline study
27. ● Following abnormal ipsilateral ICA baseline study
Asymptomatic or Stable Symptoms After Baselin
Surveillance Frequency After First Year
28. ● Following normal ipsilateral ICA baseline study
29. ● Following abnormal ipsilateral ICA baseline study
A  appropriate; I  inappropriate; ICA  internal carotid artery; U  uncertain.
Table 2.1. Limited Screening Study for Carotid Artery Plaque—
Indication
30. ● Low Framingham risk score
● No prior risk assessment imaging study, such as coronary calciu
31. ● Intermediate Framingham risk score
● No prior risk assessment imaging study, such as coronary calciu
32. ● Low or intermediate Framingham risk score
● Normal prior risk assessment imaging study, such as coronary c
33. ● High Framingham risk score
*A screening carotid duplex examination includes assessment for the presence of atherosclerot
stenosis of the proximal internal carotid artery using spectral Doppler. The screening carotid du
standards 5.1.5) (3). A screening study for carotid artery plaque does not include formal meas
A  appropriate; I  inappropriate; IMT  intima-media thickness; U  uncertain.—Asymptomatic*†
Appropriate Use Score (1–9)
I (1)
At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
A velocity) I (1) I (1) I (1)
I (1) I (1) I (1)
I (2) U (6) U (6)








A velocity) I (1) I (3) I (1)
I (2) U (5) U (6)
I (3) A (7) U (6)
A (7) A (7) U (6)
or for rapid progression of stenosis during subsequent follow-up (e.g., stenosis category change during
o be addressed in the text of the document. Periodic surveillance duplex ultrasound should be performedAppropriate Use Score (1–9)
A (8)
e Study, At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
I (2) A (7) A (7)
U (4) A (7) U (5)







I (2) A (7) U (5)
U (4) A (7) U (5)Asymptomatic*
Appropriate Use
Score (1–9)
m scoring or carotid IMT measurement
I (2)
m scoring or carotid IMT measurement
U (4)
alcium scoring or carotid IMT measurement
I (3)
U (5)
ic plaque within the common and internal carotid arteries using grey-scale imaging and assessment for
plex examination is performed using a limited but clearly defined screening protocol (see ICAVL 2010
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There was significant consensus regarding the appropriate-
ness of cerebrovascular duplex ultrasound for evaluation of
the patient with signs or clinical symptoms of cerebrovas-
cular disease (Table 1.1) with 7 of 8 clinical indications
rated as appropriate and 1 clinical indication rated as
uncertain.
Use of cerebrovascular ultrasound was rated as appropri-
ate for evaluation of the patient with suspected vertebro-
basilar occlusive disease with posterior circulation symp-
toms; although a customized cerebrovascular scanning
protocol and supplemental use of transcranial Doppler may
be needed for complete assessment of such patients. The
multisocietal consensus guidelines for the management of
patients with extracranial carotid and vertebral artery disease
recommend other imaging modalities (i.e., magnetic reso-
nance angiogram or computed tomography angiography)
rather than ultrasound as the initial imaging test for sus-
pected vertebral artery stenosis (4). Though carotid ultra-
sound was rated as appropriated for evaluation of suspected
carotid artery dissection, its use is best suited for evaluation
of suspected carotid dissection arising from dissection of the
aortic arch and extending into the arch vessels (e.g., com-
mon carotid artery). Carotid ultrasound is not recom-
mended to diagnose carotid dissection in the setting of
trauma as a distal dissection of the internal carotid artery
may not be detected by duplex scanning. In such cases,
another other imaging modality (i.e., MRA or CTA) should
be used.
Appropriateness of the use of cerebrovascular duplex
ultrasound to assess for carotid stenosis in the patient with
syncope with no obvious cardiac cause was rated as uncer-
tain by the panel. Cerebrovascular disease is an unlikely
cause of syncope but has been reported in cases of severe
(especially bilateral) internal carotid artery stenosis or severe
vertebrobasilar occlusive disease or subclavian–vertebral ar-
tery steal. The yield of cerebrovascular ultrasound in the
evaluation of syncope has been low in published case series,
but the uncertain rating for this indication reflects the need
for additional research, including cost effectiveness data, in
this area (5,6).
In contrast to the evaluation of the symptomatic patient
or patient with signs of cerebrovascular disease, there was
uncertainty regarding the use of cerebrovascular duplex for
assessment of the asymptomatic patient with risk factors or
comorbidities associated with carotid artery stenosis (Table 1.2),
with 6 of 7 indications receiving an uncertain rating and
only 1 indication receiving an appropriate rating. The
technical panel rated as uncertain all clinical scenarios for
cerebrovascular duplex examination prior to cardiac surgery,
including evaluation of any asymptomatic patient (i.e., no
prior hemispheric symptoms, no bruit) prior to CABG and
evaluation of an asymptomatic patient prior to valvular heart
surgery, including patients with or without risk factors orcomorbidities associated with cerebrovascular disease. These
findings reflect a need for more research in this arena,
particularly cost effectiveness data.
Clinical management of the asymptomatic patient with
atherosclerotic carotid disease typically includes periodic
ultrasound surveillance for progressive carotid artery stenosis
with the objective of referral for surgical (endarterectomy) or
interventional (carotid artery stenting) therapy for severe
stenosis of the internal carotid artery (7). The technical
panel reviewed the appropriateness of time points for such
surveillance studies (Table 1.3) during the first year after
initial diagnosis of carotid stenosis and during subsequent
follow-up across all severity categories. Any follow-up was
deemed inappropriate following a normal baseline carotid
examination (i.e., absent plaque or narrowing). For surveil-
lance of the patient with plaque without narrowing noted on
initial duplex examination or mild stenosis of 50%, any
surveillance during the first year of follow-up was also
deemed inappropriate, and surveillance beyond the first year
was uncertain. Ratings for time points for surveillance of
moderate (50% to 69%) and severe (70%) ICA lesions
likely reflect the lack of substantial clinical effectiveness data
in this arena, with the majority of indications rated as
uncertain. For moderate ICA lesions, repeat ultrasound
studies within the first year after diagnosis were rated as
inappropriate (at 3 to 5 months) or uncertain, with annual
studies rated as appropriate. For severe ICA lesions, an
ultrasound study at 6 months and then every 6 or 12 months
were rated as appropriate, although it should be emphasized
that at this severity of stenosis, the risks versus benefits of
revascularization (carotid artery endarterectomy or stenting)
should be considered (7).
The panel reviewed indications for cerebrovascular duplex
ultrasound after carotid artery revascularization (endarterec-
tomy or stenting). Obtaining a baseline bilateral cerebro-
vascular duplex examination was highly rated as appropriate
by the technical panel. The panel rated indications for
follow-up during the first year after revascularization and
beyond based upon whether the initial postrevascularization
duplex demonstrated normal, expected postprocedural find-
ings, or indicated a postprocedural abnormality (e.g., signifi-
cantly elevated velocities) in Table 1.4. Though not included in
the rated clinical indications, it is likely that frequency and
appropriateness of testing intervals would change in the setting
of new abnormalities identified on a surveillance duplex exam-
ination, such as significant in-stent restenosis or significant
restenosis at a carotid endarterectomy site.
The presence of carotid artery plaque with or without
stenosis has been associated with increased cardiovascular
risk in epidemiological studies, including increased risk of
myocardial infarction (8–11). The technical panel reviewed
the appropriateness of a carotid duplex screening ultrasound
examination to screen plaque and significant narrowing of
the proximal internal carotid arteries. However, these rat-
ings do not include the appropriateness of carotid intima-
medial thickness (IMT) assessment, a procedure that re-
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nor routinely performed in the clinical vascular laboratory
setting. The technical panel rated 2 indications as inappro-
priate for carotid screening ultrasound: assessment of the
patient with low Framingham risk score and assessment of
the patient with low or intermediate Framingham risk scorement (e.g., carotid IMT or coronary artery calcium
scoring). The technical panel rated assessment of the
patient with intermediate or high Framingham risk score
and without prior imaging risk assessment study as
uncertain indications for carotid ultrasound, reflecting
again the need for outcome and clinical effectiveness datawho has already undergone another imaging risk assess- for these screening indications.
Section 3. Renal and Mesenteric Artery Duplex




Creatinine Elevation and/or Hypertension
34. ● Malignant hypertension (see Assumptions) A (8)
35. ● Resistant hypertension (see Assumptions) A (8)
36. ● Worsening blood pressure control in long-standing hypertensive patient A (8)
37. ● Hypertension in young person (age 35 years) A (8)
38. ● Unexplained size discrepancy between kidneys (1.5 cm; in longest dimension) A (7)
39. ● Unknown cause of azotemia (e.g., unexplained increase in creatinine) A (7)
40. ● Increased creatinine (50% baseline or above normal levels) after the administration of ACE/ARBs A (8)
41. ● Acute renal failure with aortic dissection A (8)
42. ● Epigastric bruit A (7)
Heart Failure of Unknown Origin
43. ● Refractory CHF A (7)
44. ● “Flash” pulmonary edema A (8)
ACE  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; CHF  congestive heart failure.




45. ● Atherosclerotic vascular disease in other beds (e.g., peripheral artery disease) and well-controlled hypertension I (3)
46. ● Unexplained size discrepancy between kidneys (1.5 cm; in longest dimension)as discovered by CT or ultrasound U (4)
CT  computed tomography; I  inappropriate; U  uncertain.





47. ● Evaluate for acute abdominal pain “out of proportion to exam”
● Leukocytosis, “thumbprinting,” pneumatosis or hemoconcentration, and acidosis with or without elevated amylase,
alkaline phosphatase, or CPK
I (3)
48. ● Postprandial pain or weight loss not otherwise explained
● GI evaluation previously completed
A (8)
49. ● Postprandial pain or discomfort
● GI evaluation not yet undertaken
U (5)
50. ● Chronic constipation or diarrhea
● GI evaluation not yet undertaken
I (3)
51. ● Unexplained or unintended weight loss U (5)
52. ● Abdominal or epigastric bruit U (4)
A  appropriate; CPK  creatine phosphokinase; GI  gastrointestinal; I  inappropriate; U  uncertain.
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In this section, the ratings were found to be appropriate for
the hypertension, creatinine, and heart failure indications in
evaluating for renal artery stenosis. The only appropriate
indication for duplex investigation of mesenteric artery
stenosis was for the patients with symptoms of postprandial
pain and weight loss and who have undergone a gastroin-
Table 3.4. Follow–Up Testing for Renal Artery Stenosis—Asym
Indication
53. ● Prior imaging indicates renal artery stenosis
● Determine hemodynamic significance
54. ● Surveillance of known renal artery stenosis
A  appropriate; U  uncertain.
Table 3.5. Surveillance After Renal or Mesenteric Artery Revas
Indication
Asym
55. ● Baseline surveillance (within 1 month) after revascularization
New or Worsening S
56. ● After renal or mesenteric artery revascularization
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance
57. ● During first 12 months after endovascular revascularization
Asymptomatic or Stable Symptoms After Baseline Study, Surveillanc
58. ● After first 12 months after endovascular revascularization
A  appropriate; I  inappropriate; U  uncertain.A  appropriate; I  inappropriate; U  uncertain.teric artery revascularization was deemed to be appropriate
at 1 month following the procedure to establish a baseline
and any time there are new signs or symptoms. Surveillance
every 12 months was the only follow-up time frame rated
appropriate after endovascular and surgical revasculariza-
tion. Routine surveillance following surgical renal or mes-












ency During First Year At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
I (3) U (6) U (6)







I (3) A (7) U (5)testinal (GI) evaluation. Surveillance after renal or mesen- absence of recurrent or worsening symptoms.
Section 4. Aortic and Aortoiliac Duplex




59. ● Lower extremity claudication A (7)
60. ● Nonspecific lower extremity discomfort I (3)
61. ● New onset abdominal or back pain U (6)
62. ● Aneurysmal femoral or popliteal pulse A (8)
63. ● Pulsatile abdominal mass A (9)
64. ● Decreased or absent femoral pulse A (7)
65. ● Abdominal or femoral bruit A (7)
66. ● Fever of unknown origin I (3)
67. ● Lower extremity swelling I (2)
68. ● Evidence of atheroemboli in the lower extremities, including ischemic toes A (8)
69. ● Erectile dysfunction U (4)
70. ● Abnormal physiologic testing indicating aortoiliac occlusive disease A (8)
71. ● Hypertension I (3)
72. ● Abnormal abdominal x-ray suggestive of aneurysm A (8)
73. ● Presence of a lower extremity arterial aneurysm (e.g., femoral or popliteal) A (8)
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75. ● Men age 60 years
● First degree relative with an abdominal aortic aneurysm
A (8)
76. ● Women age 60 years
● First degree relative with an abdominal aortic aneurysm
A (8)
77. ● Men age 65 to 75 years
● Current or former smoker
A (8)
78. ● Women age 65 to 75 years
● Current or former smoker
A (7)
79. ● Age 75 years
● Current or former smoker
A (7)
80. ● Age 65 years
● No history of smoking
U (5)
81. ● Age 65 years
● No history of smoking
I (3)A  appropriate; I  inappropriate; U  uncertain.Table 4.3. Surveillance of Known Abdominal Aortic Aneurysm
Indication Appropriate Use Score (1–9)
New or Worsening Symptoms
82. ● Known abdominal aortic aneurysm (any size) A (9)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
83. ● Men, aneurysm 3.0 to 3.9 cm in diameter I (1) U (4) A (7)
84. ● Women, aneurysm 3.0 to 3.9 cm in diameter I (1) U (4) A (7)
85. ● Aneurysm 4.0 to 5.4 cm in diameter U (4) A (7) A (7)
86. ● Aneurysm 5.5 cm in diameter A (7) A (7) U (6)









87. ● Men, aneurysm 3.0 to 3.9 cm in diameter I (2) A (7) A (7)
88. ● Women, aneurysm 3.0 to 3.9 cm in diameter I (2) A (7) A (7)
89. ● Aneurysm 4.0 to 5.4 cm in diameter U (5) A (7) U (6)
90. ● Aneurysm 5.5 cm in diameter A (8) A (7) U (5)









91. ● Men, aneurysm 3.0 to 3.9 cm in diameter A (7) A (7) U (4)
92. ● Women, aneurysm 3.0 to 3.9 cm in diameter A (8) A (7) U (4)
93. ● Aneurysm 4.0 to 5.4 cm in diameter A (8) A (7) U (4)
94. ● Aneurysm 5.5 cm in diameter A (9) U (5) I (3)A  appropriate; I  inappropriate; U  uncertain.
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Signs and symptoms considered as appropriate indications
for duplex evaluation of the abdominal aorta and iliac
arteries included intermittent claudication, an aneurysmal
femoral or popliteal pulse, a pulsatile abdominal mass, a
decreased or absent femoral pulse, and an abdominal or
femoral bruit. Inappropriate indications included nonspe-
cific lower extremity discomfort, fever of unknown origin,
lower extremity swelling, and hypertension. Erectile dys-
function was the only indication rated as uncertain.
Ultrasound screening of asymptomatic individuals for ab-
dominal aortic aneurysms was considered appropriate in men
and women over age 60 who were known to have first-degree
relatives with an abdominal aortic aneurysm. Screening was
also appropriate for men and women between 65 and 75 years
of age who were current or former smokers and any current or
former smoker over age 75. However, ultrasound screening
was inappropriate for individuals under age 65 with no history of
smoking. There was uncertainty over the role of screening for
those age 65 and older with no history of smoking.
The reviewers concurred with the primary recommenda-
tion of the U.S. Preventive Services Task Force (USPSTF)
that screening for abdominal aortic aneurysms was appro-
priate for men aged 65 to 75 years who had ever smoked
(12). However, the reviewers also considered screening
appropriate in both men and women who had a first-degree
relative with an abdominal aortic aneurysm, a situation that
was acknowledged in the USPSTF report by stating that
“clinicians must individualize recommendations depending
on a patient’s risk and likelihood of benefit.” Although the
reviewers rated aneurysm screening as appropriate in women
aged 65 to 75 years who were current or former smokers, the
USPSTF recommended against routine screening in
women, based on the low prevalence of large abdominal
Table 4.4. Surveillance After Aortic Endograft or Aortoiliac Ste
Indication
Baseline (Within 1 Mo
95. ● Aortic or iliac endograft
96. ● Aortic and iliac artery stents
New or Worsening Lower Extre
97. ● Aortic or iliac endograft
98. ● Aortic and iliac artery stents
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance
99. ● Aortic endograft without endoleak stable and/or decreasing res
100. ● Aortic endograft with endoleak and/or increasing residual aneu
101. ● Aortic or iliac artery stents
Asymptomatic or Stable Symptoms After Baseline Study, Surveillanc
102. ● Aortic endograft without endoleak stable and/or decreasing res
103. ● Aortic endograft with endoleak and/or increasing residual aneu
104. ● Aortic or iliac artery stents
A  appropriate; I  inappropriate; U  uncertain.aortic aneurysms and concern that the harms of screeningoutweighed the benefits. The reviewers also considered
screening appropriate for patients over 75 years of age who
were current or former smokers, even though the USPSTF
set an upper age limit for screening of 75 years, since the
increased prevalence of comorbidities would decrease the chances
that older patients would benefit from screening. It is important to
note that the purpose of the USPSTF recommendations differ
from that of this AUC document. The USPSTF provides
guidance on whether population-based screening is generally
recommended whereas AUC look at how reasonable testing may
be for specific patient populations.
The reviewers’ ratings were generally consistent with
recommendations for aneurysm screening from the Society
for Vascular Surgery (SVS) and the American College of
Cardiology (ACC)/American Heart Association (AHA)
2005 Practice Guidelines (13,14). The SVS recommends
1-time ultrasound screening for all men at age 65 or older,
or at age 55 or older for men with a positive family history
for abdominal aortic aneurysms. For women, the SVS
recommends screening at age 65 or older if they have ever
smoked or have a positive family history. The ACC/AHA
guidelines recommend aneurysm screening for high-risk
populations, defined as men 60 years of age or older with
first-degree relatives who have abdominal aortic aneurysms
and men 65 to 75 years of age who have ever smoked.
For surveillance of a known abdominal aortic aneurysm of
any size, duplex ultrasound was rated as appropriate. When
patients who were asymptomatic or had stable symptoms
were considered according to aneurysm size and surveillance
frequency, follow-up at 9 to 12 months after a baseline study
was rated as appropriate for aneurysms 3.0 cm to 3.9 cm in
diameter in both men and women. Earlier follow up at 3 to
5 months after a baseline study was inappropriate, and the
value of follow-up at 6 to 8 months was uncertain. After the




ymptoms After Baseline Exam
A (8)
A (8)
ency During First Year At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
neurysm sac size I (3) U (5) U (6)
ac size U (6) A (8) A (7)
I (2) U (5) U (6)







neurysm sac size I (3) A (7) U (5)
ac size A (8) A (7) U (5)








rysm sfirst year, follow-up was rated as appropriate for aneurysms
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24-month intervals for those patients with no or slow
progression during the first year.
For patients with aneurysms of 4.0 cm to 5.4 cm,
surveillance at intervals of 6 to 8 months or 9 to 12 months
after a baseline study was appropriate. Surveillance for
aneurysms of 5.5 cm or more in diameter was appropriate at
3 to 5 months and 6 to 8 months in the first year and
intervals of 6 months and 12 months after the first year,
assuming no or slow progression. When rapid progression
was observed on serial studies, follow-up was appropriate at
6-month and 12-month intervals for aneurysms 3.0 cm to
3.9 cm in diameter and those 4.0 cm to 5.4 cm in diameter.
However, for aneurysms of 5.5 cm or more in diameter with
rapid progression, follow up was rated as appropriate only at
6-month intervals, whereas the value of follow-up at 12-
month intervals was uncertain, and follow-up at 24-month
intervals was inappropriate. Since patients with aneurysms
of 5.5 cm or more in diameter are usually considered for
elective repair, the role of continued surveillance must be
individualized. If a patient has reversible or time-limited
factors that prevent elective aneurysm repair, then ongoing
surveillance may play a role in clinical decision making.
However, if a patient declines elective repair, or is not
considered a candidate for repair under any circumstances,
then the value of surveillance is questionable.After an aortic endograft or aortoiliac stenting, duplex
scanning was appropriate as a baseline study (within 1
month), as well as for any subsequent new or worsening
lower extremity symptoms. For aortic endograft patients
with stable or decreasing residual aneurysm sac size and
without evidence of endoleak during the first year, duplex
follow-up was rated as inappropriate at 3 to 5 months and
uncertain at both 6 to 8 months and 9 to 12 months.
However, in the presence of an endoleak or increasing
residual aneurysm sac size during the first year, follow-up
was considered appropriate at either at 6 to 8 months or 9
to 12 months. For asymptomatic patients and those with
stable symptoms during the first year after aortic or iliac
artery stenting, duplex follow-up was rated as inappropriate
at 3 to 5 months and uncertain at 6 to 8 months and 9 to 12
months. Similarly, follow-up every 6 months or 12 months
was inappropriate and follow-up every 24 months or greater
was considered as uncertain for aortic or iliac artery stent
patients who were asymptomatic or had stable symptoms
after the first year. Follow-up of aortic endografts without
evidence of endoleak and stable or decreasing residual
aneurysm sac size after the first year was appropriate at
12-month intervals. When there was an endoleak or increasing
residual aneurysm sac size after the first year, follow-up was
appropriate at either 6-month or 12-month intervals.Section 5. Lower Extremity Artery Testing Using Multilevel Physiological Testing Alone
or Duplex Ultrasound With Single-Level ABI and PVR




105. ● Lower extremity claudication A (9)
106. ● Leg/foot/toe pain at rest A (9)
107. ● Foot or toe ulcer or gangrene A (9)
108. ● Infection of leg/foot without palpable pulses A (9)
109. ● Suspected acute limb ischemia (e.g., cold, painful limb with pallor, pulselessness, parasthesias) A (9)
110. ● Nocturnal leg cramps
● Normal pulses
I (2)
111. ● Lack of hair growth on dorsum of foot or toes
● Normal pulses
I (2)
112. ● Evidence of atheroemboli in the lower extremities A (8)
113. ● Lower extremity swelling
● Normal pulses
I (2)
114. ● Diabetes with peripheral neuropathy
● Normal pulses
I (3)
A  appropriate; I  inappropriate.
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Table 5.2. Surveillance of Known Lower Extremity PAD
Indication Appropriate Use Score (1–9)
New or Worsening Symptoms
115. ● Normal baseline study A (7)
116. ● Abnormal baseline ABI (i.e., ABI 0.90) A (8)
No Change in Symptom Status (No revascularization)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
117. ● Normal baseline ABI (no stenosis) I (1) I (1) I (1)
118. ● Mild or moderate disease (e.g., ABI 0.4) I (2) I (2) U (4)
119. ● Severe (e.g., ABI 0.4) I (3) U (5) U (5)







120. ● Normal baseline ABI (no stenosis) I (1) I (1) I (2)
121. ● Mild or moderate disease (e.g., ABI 0.4) I (2) I (2) U (4)
122. ● Severe (e.g., ABI 0.4) U (4) U (4) I (3)
A  appropriate; ABI  ankle-brachial index; I  inappropriate; PAD  peripheral artery disease; U  uncertain.
Table 5.3. Surveillance of Lower Extremity PAD After Revascularization (Duplex/ABI)
Indication Appropriate Use Score (1–9)
123. ● Baseline surveillance (within 1 month) A (8)
New or Worsening Symptoms
124. ● After revascularization (angioplasty  stent or bypass) A (9)
Asymptomatic or Stable Symptoms
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
125. ● After angioplasty  stent placement I (2) U (6) U (6)
126. ● After vein bypass graft U (6) A (8) U (6)
127. ● After prosthetic bypass graft U (5) A (7) U (5)







128. ● After angioplasty  stent placement I (3) A (7) U (5)
129. ● After vein bypass graft U (5) A (7) U (5)
130. ● After prosthetic bypass graft I (3) A (7) U (5)
A  appropriate; I  inappropriate; PAD  peripheral artery disease; U  uncertain.




131. ● Diminished pulses A (7)
132. ● Femoral bruit A (7)
A  appropriate.
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133. ● Age 50 years
● With diabetes
A (7)
134. ● Age 50 years
● With diabetes
U (5)
135. ● Age 50 years
● Cigarette smoking (current or past)
A (7)
136. ● Age 70 years A (7)
A  appropriate; U  uncertain.




137. ● Pulsatile groin mass A (9)
138. ● Bruit or thrill over the groin A (8)
139. ● Ecchymosis U (4)
140. ● Significant hematoma A (7)
141. ● Severe pain within groin post procedure A (7)
A  appropriate; U  uncertain.




142. ● Arm or hand claudication A (8)
143. ● Finger discoloration or ulcer A (8)
144. ● Unilateral cold painful hand A (8)
145. ● Raynaud’s phenomenon U (5)
146. ● Suspected positional arterial obstruction (e.g., thoracic outlet syndrome) A (7)
147. ● Upper extremity trauma with suspicion of vascular injury A (8)
148. ● Discrepancy in arm pulses or blood pressure discrepancy of20mmHg between arms U (6)
149. ● Periclavicular bruit U (5)
150. ● Pre-op radial artery harvest (e.g., for CABG) A (7)
151. ● Presence of pulsatile mass or hand ischemia after upper extremity vascular access A (8)
152. ● Presence of bruit after upper extremity access for intervention A (8)
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The screening of asymptomatic individuals with ABI alone
in this document is also addressed by the USPSTF. The
rating of “uncertain” in this document is not consistent with
that of the USPSTF where this type of evaluation was not
deemed appropriate, or level D. There have been published
responses to the USPSTF stance pointing out that ABI
evaluation of certain populations would identify a high-risk
group for heart attack, stroke, and death (15). The ACC/
AHA guidelines and the American Diabetes Association
Guidelines advocate ABI testing in certain disease popula-
tions such as those age 50 years with diabetes or chronic
smoking. The designation of “uncertain” in this document is
reflective of a paucity of data regarding ABI evaluation
alone in asymptomatic individuals and effect on prevention
of claudication and limb loss. The designation of “uncer-
tain” is not meant to address the potential impact of ABI
evaluation on heart attack and stroke outcome. The AUC
ratings are meant to determine when diagnostic testing may
be a reasonable option under certain clinical circumstances.
They are not intended to endorse or imply population-wide
screening protocols that are the focus of the USPSTF.
The appropriate indications for lower extremity testing using
multilevel physiological methods alone or duplex ultrasound with
single-level ABI and pulse volume recording (PVR) were clearly
delineated by the reviewers with 6 appropriate and 4 inappropri-
ate. None of the indications were deemed uncertain. Nocturnal leg
cramps, neuropathy, lower extremity swelling or hair loss in the
setting of normal pulses are not clinical scenarios that support
ordering lower extremity artery tests.
There are 2 clear appropriate indications for surveillance
of known lower extremity arterial disease, patients with
either a normal ABI or an abnormal ABI with new or
worsening symptoms. A short follow-up interval of every 6
Table 8.2. Surveillance of Upper Extremity PAD After Revascul
Indication
153. ● Baseline (within 1 month)
New or Wors
154. ● After revascularization (stent or bypass)
155. ● Post trauma
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance
156. ● After vein bypass graft
157. ● After prosthetic bypass graft
Asymptomatic or Stable Symptoms After Baseline Study, Surveillanc
158. ● After vein bypass graft
159. ● After prosthetic bypass graft
A  appropriate; I  inappropriate; PAD  peripheral artery disease; U  uncertain.months is not indicated, whereas it was uncertain whether mevery 12 months or every 24 months or greater was appropriate
for follow-up testing. A baseline study after lower extremity
revascularization was deemed appropriate, as was testing for
new or worsening symptoms after revascularization. A
follow-up interval for surveillance after baseline evaluation was
thought most appropriate at 12 months if the patient is stable
without new or worsening symptoms. The most appropriate
time for surveillance after lower extremity prosthetic or vein
bypass graft was 6to 8 months after the procedure.
The appropriate indications for lower extremity artery testing
with ABI only were diminished pulses, femoral bruit, age 50
years with diabetes or smoking, and age 70 years, which is
onsistent with ACC/AHA peripheral artery disease (PAD)
uidelines. The evaluation with ABI only for those age50 years
ith diabetes was uncertain.
The appropriate indications for lower extremity duplex ultra-
ound evaluation only included a pulsatile groin mass, bruit or
hrill, significant hematoma, or groin pain postprocedure. The
resence of ecchymosis only was an uncertain indication.
The appropriate indications for upper extremity arterial
esting included claudication, ulcer, unilateral cold painful
and, suspected positional arterial obstruction, and trauma
ith suspicion of vascular injury. The presence of Raynaud’s
henomenon was an uncertain indication. A preoperative
valuation for a procedure such as radial artery harvest or
uspected complication after an upper extremity arterial
ntervention was also appropriate indications for testing.
Similar to the lower extremity, a baseline study after
evascularization and new or worsening symptoms are ap-
ropriate indications for upper extremity arterial testing.
he most appropriate initial surveillance time interval after
pper extremity revascularization with either vein or pros-
hetic bypass graft was at 12 months. A surveillance period
f every 6 months after initial postoperative evaluation was
tion





ency During First Year At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
U (6) A (7) U (5)
I (3) U (6) U (4)







U (4) A (7) U (5)
U (4) A (7) U (4)ariza
ening
Frequ
e Freqost inappropriate for asymptomatic patients.
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Evaluation for Cerebrovascular Disease—Potential Signs and/or Symptoms
1. ● New or worsening hemispheric neurological symptoms (e.g., unilateral motor or sensory deficit, speech impairment, or
amaurosis fugax)
● Evaluation of transient ischemic attack or stroke
A (9)
2. ● Hollenhorst plaque visualized on retinal examination A (8)
3. ● Lightheadedness or impaired vision in the setting of upper extremity exertion
● Evaluation for subclavian-vertebral steal phenomenon
A (7)
5. ● Suspected symptomatic vertebrobasilar occlusive disease in the symptomatic patient (e.g., vertigo, ataxia, diplopia,
dysphagia, dysarthria)
A (7)
6. ● Evaluation for suspected carotid artery dissection A (8)
7. ● Pulsatile neck mass A (8)
8. ● Cervical bruit
● No prior carotid artery assessment
A (7)
Evaluation for Cerebrovascular Disease—Asymptomatic With Comorbidities or Risk Factors for Carotid Artery Stenosis
9. ● No cervical bruit
● Atherosclerotic disease in other vascular beds (e.g., lower extremity PAD, coronary artery disease, abdominal aortic aneurysm)
A (7)
Follow-up or Surveillance for Carotid Artery Stenosis—Asymptomatic*†
Surveillance Frequency During First Year
20. ● Severe ICA stenosis (e.g., 70% to 99%)
● At 6 to 8 months
A (7)
Surveillance Frequency After First Year
23. ● Moderate ICA stenosis (e.g., 50% to 69%)
● Every 12 months
A (7)
24. ● Severe ICA stenosis (e.g., 70% to 99%)
● Every 6 months
A (7)
24. ● Severe ICA stenosis (e.g., 70% to 99%)
● Every 12 months
A (7)
Surveillance After Carotid Artery Intervention
Surveillance Frequency During First Year
25. ● Baseline (within 1 month) after carotid intervention A (8)
26. ● Following normal ipsilateral ICA baseline study
● Surveillance at 6 to 8 months
A (7)
26. ● Following normal ipsilateral ICA baseline study
● Surveillance at 9 to 12 months
A (7)
27. ● Following abnormal ipsilateral ICA baseline study
● Surveillance at 6 to 8 months
A (7)
Surveillance Frequency After First Year
28. ● Following normal ipsilateral ICA baseline study
● Surveillance every 12 months
A (7)
29. ● Following abnormal ipsilateral ICA baseline study
● Surveillance every 12 months
A (7)
Renal and Mesenteric Artery Duplex
Evaluation for Renal Artery Stenosis—Potential Signs and/or Symptoms
Creatinine Elevation and/or Hypertension
34. ● Malignant hypertension (160/80 mm Hg) A (8)
35. ● Resistant hypertension (140/90 mm Hg on 3 meds) A (8)
36. ● Worsening blood pressure control in long-standing hypertensive patient A (8)
37. ● Hypertension in young person (age 35 years) A (8)
38. ● Unexplained size discrepancy between kidneys (1.5 cm; in longest dimension) A (7)
39. ● Unknown cause of azotemia (e.g., unexplained increase in creatinine) A (7)
40. ● Increased creatinine (50% baseline or above normal levels) after the administration of ACE/ARBs A (8)
41. ● Acute renal failure with aortic dissection A (8)
42. ● Epigastric bruit A (7)
260 Mohler III et al. JACC Vol. 60, No. 3, 2012




Heart Failure of Unknown Origin
43. ● Refractory heart failure A (7)
44. ● “Flash” pulmonary edema A (8)
Evaluation for Mesenteric Artery Stenosis—Potential Signs and/or Symptoms
Symptomatic
48. ● Post prandial pain or weight loss not otherwise explained
● GI evaluation previously completed
A (8)
Follow-up Testing for Renal Artery Stenosis—Asymptomatic
53. ● Prior imaging indicates renal artery stenosis
● Determine hemodynamic significance
A (7)
Surveillance After Renal or Mesenteric Artery Revascularization
Asymptomatic
55. ● Baseline surveillance (within 1 month) after revascularization A (8)
New or Worsening Symptoms After Baseline
56. ● After renal or mesenteric artery revascularization A (8)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
58. ● After first 12 months after endovascular revascularization
● Surveillance every 12 months
A (7)
Aortic and Aortoiliac Duplex
Evaluation for Abdominal Aortic Disease—Signs and/or Symptoms
59. ● Lower extremity claudication A (7)
62. ● Aneurysmal femoral or popliteal pulse A (8)
63. ● Pulsatile abdominal mass A (9)
64. ● Decreased or absent femoral pulse A (7)
65. ● Abdominal or femoral bruit A (7)
68. ● Evidence of atheroemboli in the lower extremities, including ischemic toes A (8)
70. ● Abnormal physiologic testing indicating aortoiliac occlusive disease A (8)
72. ● Abnormal abdominal x-ray suggestive of aneurysm A (8)
73. ● Presence of a lower extremity arterial aneurysm (e.g., femoral or popliteal) A (8)
74. ● Presence of a thoracic aortic aneurysm A (8)
Screening for Abdominal Aortic Aneurysm—Asymptomatic
75. ● Men age 60 years
● First degree relative with an abdominal aortic aneurysm
A (8)
76. ● Women age 60 years
● First degree relative with an abdominal aortic aneurysm
A (8)
77. ● Men age 65 to 75 years
● Current or former smoker
A (8)
78. ● Women age 65 to 75 years
● Current or former smoker
A (7)
79. ● Age 75 years
● Current or former smoker
A (7)
Surveillance of Known Abdominal Aortic Aneurysm
New or Worsening Symptoms
82. ● Known abdominal aortic aneurysm (any size) A (9)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
83. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 9 to 12 months
A (7)
84. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 9 to 12 months
A (7)
85. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance at 6 to 8 months
A (7)
85. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance at 9 to 12 months
A (7)
86. ● Aneurysm 5.5 cm in diameter
● Surveillance at 3 to 5 months
A (7)
86. ● Aneurysm 5.5 cm in diameter
● Surveillance at 6 to 8 months
A (7)
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Asymptomatic or Stable Symptoms, No or Slow Progression During First Year, Surveillance Frequency After First Year
87. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 12 months
A (7)
87. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 24 months or greater
A (7)
88. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 12 months
A (7)
88. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 24 months or greater
A (7)
89. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 12 months
A (7)
90. ● Aneurysm 5.5 cm in diameter
● Surveillance every 6 months
A (8)
90. ● Aneurysm 5.5 cm in diameter
● Surveillance every 12 months
A (7)
Asymptomatic or Stable Symptoms, Rapid Progression During First Year, Surveillance Frequency After First Year
91. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 6 months
A (7)
91. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 12 months
A (7)
92. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 6 months
A (8)
92. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 12 months
A (7)
93. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 6 months
A (8)
93. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 12 months
A (7)
94. ● Aneurysm 5.5 cm in diameter
● Surveillance every 6 months
A (9)
Surveillance After Aortic Endograft or Aortoiliac Stenting
Baseline (Within 1 Month After the Intervention)
95. ● Aortic or iliac endograft A (8)
96. ● Aortic and iliac artery stents A (7)
New or Worsening Lower Extremity Symptoms After Baseline Exam
97. ● Aortic or iliac endograft A (8)
98. ● Aortic and iliac artery stents A (8)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
100. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size
● Surveillance at 6 to 8 months
A (8)
100. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size
● Surveillance at 9 to 12 months
A (7)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
102. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance every 12 months
A (7)
103. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size
● Surveillance every 6 months
A (8)
103. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size
● Surveillance every 12 months
A (7)
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Lower Extremity Artery Testing Using Multilevel Physiological Testing Alone or Duplex Ultrasound With Single Level ABI
and PVR Evaluation for Lower Extremity Atherosclerotic Disease—Potential Signs and/or Symptoms
105. ● Lower extremity claudication A (9)
106. ● Leg/foot/toe pain at rest A (9)
107. ● Foot or toe ulcer or gangrene A (9)
108. ● Infection of leg/foot without palpable pulses A (9)
109. ● Suspected acute limb ischemia (e.g., cold, painful limb with pallor, pulselessness, parasthesias) A (9)
112. ● Evidence of atheroemboli in the lower extremities A (8)
Surveillance of Known Lower Extremity PAD
New or Worsening Symptoms
115. ● Normal baseline study A (7)
116. ● Abnormal baseline ABI (i.e, ABI 0.90) A (8)
Surveillance of Lower Extremity PAD After Revascularization (Duplex/ABI)
123. ● Baseline Surveillance (within 1 month) A (8)
New or Worsening Symptoms
124. ● After revascularization (angioplasty  stent or bypass) A (9)
Asymptomatic or Stable Symptoms
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
126. ● After vein bypass graft
● Surveillance at 6 to 8 months
A (8)
127. ● After prosthetic bypass graft
● Surveillance at 6 to 8 months
A (7)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
128. ● After angioplasty  stent placement
● Surveillance every 12 months
A (7)
129. ● After vein bypass graft
● Surveillance every 12 months
A (7)
130. ● After prosthetic bypass graft
● Surveillance every 12 months
A (7)
Lower Extremity Artery Testing With ABI Only
Screening for Lower Extremity Atherosclerotic Disease—Potential Signs
131. ● Diminished pulses A (7)
132. ● Femoral bruit A (7)
Lower Extremity Artery Testing With ABI Only
Screening for Lower Extremity Atherosclerotic Disease—Asymptomatic With Comorbidities
133. ● Age 50 years
● With diabetes
A (7)
135. ● Age 50 years
● Cigarette smoking (current or past)
A (7)
136. ● Age 70 years A (7)
Lower Extremity Artery Testing With Duplex Ultrasound Only
Evaluation for Groin Complication After Femoral Access
137. ● Pulsatile groin mass A (9)
138. ● Bruit or thrill over the groin A (8)
140. ● Significant hematoma A (7)
141. ● Severe pain within groin post procedure A (7)
Upper Extremity Arterial Testing—Physiological Testing or Duplex Ultrasound Study
Evaluation for Upper Extremity PAD—Potential Signs and/or Symptoms
142. ● Arm or hand claudication A (8)
143. ● Finger discoloration or ulcer A (8)
144. ● Unilateral cold painful hand A (8)
146. ● Suspected positional arterial obstruction (e.g., thoracic outlet syndrome) A (7)
147. ● Upper extremity trauma with suspicion of vascular injury A (8)
150. ● Pre-op radial artery harvest (e.g., for CABG) A (7)
263JACC Vol. 60, No. 3, 2012 Mohler III et al.




151. ● Presence of pulsatile mass or hand ischemia after upper extremity vascular access A (8)
152. ● Presence of bruit after upper extremity access for intervention A (8)
Upper Extremity Arterial Testing—Physiological Testing or Duplex Ultrasound Study
Surveillance of Upper Extremity PAD After Revascularization
153. Baseline (within 1 month) A (8)
New or Worsening Symptoms
154. ● After revascularization (stent or bypass) A (8)
155. ● Post trauma A (8)
156. ● After vein bypass graft
● Surveillance at 6 to 8 months
A (7)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
158. ● After vein bypass graft
● Surveillance every 12 months
A (7)
159. ● After prosthetic bypass graft
● Surveillance every 12 months
A (7)
*In the setting of interval development of clinical symptoms in a previously asymptomatic patient or for rapid progression of stenosis during subsequent follow-up (e.g., stenosis category change during
a limited period of time), more intensive surveillance may be indicated. †Carotid artery occlusion to be addressed in the text of the document. Periodic surveillance duplex ultrasound should be performed
according to the severity of stenosis of the contralateral side.A  appropriate; ABI  ankle-brachial index; ACE  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; CABG  coronary artery bypass graft; CHF  congestive heart





Evaluation for Cerebrovascular Disease—Potential Signs and/or Symptoms
4. ● Syncope of uncertain cause after initial cardiovascular evaluation U (5)
Evaluation for Cerebrovascular Disease—Asymptomatic with Comorbidities or Risk Factors for Carotid Artery Stenosis
10. ● No cervical bruit
● History of neck irradiation 10 years ago
U (5)
11. ● Known renal fibromuscular dysplasia U (5)
Prior to Open Heart Surgery
12. ● Planned coronary artery bypass grafting (CABG) U (6)
13. ● Atherosclerotic disease in other vascular beds (e.g., lower extremity PAD, coronary artery disease, abdominal aortic
aneurysm), or history of neck irradiation  10 years ago
● Planned valve repair/replacement surgery (without CABG)
U (6)
14. ● Atherosclerotic risk factors present
● Planned valve repair/replacement surgery (without CABG)
U (6)
15. ● No atherosclerotic risk factors
● Planned valve repair/replacement surgery (without CABG)
U (4)
Follow-Up or Surveillance for Carotid Artery Stenosis—Asymptomatic*†
Surveillance Frequency During First Year
19. ● Moderate ICA stenosis (e.g., 50% to 69%)
● At 6 to 8 months
U (6)
19. ● Moderate ICA stenosis (e.g., 50% to 69%)
● At 9 to 12 months
U (6)
20. ● Severe ICA stenosis (e.g., 70% to 99%)
● At 3 to 5 months
U (5)
20. ● Severe ICA stenosis (e.g., 70% to 99%)
● At 9 to 12 months
U (6)
Surveillance Frequency After First Year
21. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● Every 24 months or greater
U (5)
22. ● Mild ICA stenosis (e.g., 50%)
● Every 12 months
U (5)
22. ● Mild ICA stenosis (e.g., 50%)
● Every 24 months or greater
U (6)
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23. ● Moderate ICA stenosis (e.g., 50% to 69%)
● Every 24 months or greater
U (6)
24. ● Severe ICA stenosis (e.g., 70% to 99%)
● Every 24 months or greater
U (6)
Surveillance After Carotid Artery Intervention
27. ● Following abnormal ipsilateral ICA baseline study
● Surveillance at 3 to 5 months
U (4)
27. ● Following abnormal ipsilateral ICA baseline study
● Surveillance at 9 to 12 months
U (5)
Surveillance Frequency After First Year
28. ● Following normal ipsilateral ICA baseline study
● Surveillance every 24 months or greater
U (5)
29. ● Following abnormal ipsilateral ICA baseline study
● Surveillance every 6 months
U (4)
29. ● Following abnormal ipsilateral ICA baseline study
● Surveillance every 24 months or greater
U (5)
Carotid Duplex Screening Ultrasound
Limited Screening Study for Carotid Artery Plaque—Asymptomatic‡
31. ● Intermediate Framingham risk score
● No prior risk assessment imaging study, such as coronary calcium scoring or carotid IMT measurement
U (4)
33. ● High Framingham risk score U (5)
Screening for Renal Artery Stenosis—Asymptomatic
46. ● Unexplained size discrepancy between kidneys (1.5 cm; in longest dimension) as discovered by CT or ultrasound U (4)
Evaluation for Mesenteric Artery Stenosis—Potential Signs and/or Symptoms
Symptomatic
49. ● Post prandial pain or discomfort
● GI evaluation not yet undertaken
U (5)
51. ● Unexplained or unintended weight loss U (5)
52. ● Abdominal or epigastric bruit U (4)
Follow-up Testing for Renal Artery Stenosis—Asymptomatic
54. ● Surveillance of known renal artery stenosis U (6)
Surveillance After Renal or Mesenteric Artery Revascularization
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
57. ● During first 12 months after endovascular revascularization
● Surveillance at 6 to 8 months
U (6)
57. ● During first 12 months after endovascular revascularization
● Surveillance at 9 to 12 months
U (6)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
58. ● After first 12 months after endovascular revascularization
● Surveillance every 24 months or greater
U (5)
Aortic and Aortoiliac Duplex
Evaluation for Abdominal Aortic Disease—Signs and/or Symptoms
61. ● New onset abdominal or back pain U (6)
69. ● Erectile dysfunction U (4)
Screening for Abdominal Aortic Aneurysm—Asymptomatic
80. ● Age 65 years
● No history of smoking
U (5)
Surveillance of Known Abdominal Aortic Aneurysm
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
83. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 6 to 8 months
U (4)
84. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 6 to 8 months
U (4)
85. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance at 3 to 5 months
U (4)
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86. ● Aneurysm 5.5 cm in diameter
● Surveillance at 9 to 12 months
U (6)
Asymptomatic or Stable Symptoms, No or Slow Progression During First Year, Surveillance Frequency After First Year
89. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 6 months
U (5)
89. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 24 months or greater
U (6)
90. ● Aneurysm 5.5 cm in diameter
● Surveillance every 24 months or greater
U (5)
Asymptomatic or Stable Symptoms, Rapid Progression During First Year, Surveillance Frequency After First Year
91. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 24 months or greater
U (4)
92. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 24 months or greater
U (4)
93. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 24 months or greater
U (4)
94. ● Aneurysm 5.5 cm in diameter
● Surveillance every 12 months
U (5)
Surveillance After Aortic Endograft or Aortoiliac Stenting
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
99. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance at 6 to 8 months
U (5)
99. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance at 9 to 12 months
U (6)
100. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size
● Surveillance at 3 to 5 months
U (6)
101. ● Aortic or iliac artery stents
● Surveillance at 6 to 8 months
U (5)
101. ● Aortic or iliac artery stents
● Surveillance at 9 to 12 months
U (6)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
102. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance every 24 months or greater
U (5)
103. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size
● Surveillance every 24 months or greater
U (5)
104. ● Aortic or iliac artery stents
● Surveillance every 12 months
U (5)
104. ● Aortic or iliac artery stents
● Surveillance every 24 months or greater
U (5)
Surveillance of Known Lower Extremity PAD
No Change in Symptom Status (No Revascularization)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
118. ● Mild or moderate disease (e.g., ABI 0.4)
● Surveillance at 9 to 12 months
U (4)
119. ● Severe (e.g., ABI 0.4)
● Surveillance at 6 to 8 months
U (5)
119. ● Severe (e.g., ABI 0.4)
● Surveillance at 9 to 12 months
U (5)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
121. ● Mild or moderate disease (e.g., ABI 0.4)
● Surveillance every 24 months or greater
U (4)
122. ● Severe (e.g., ABI 0.4)
● Surveillance every 6 months
U (4)
122. ● Severe (e.g., ABI 0.4)
● Surveillance every 12 months
U (4)
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Surveillance of Lower Extremity PAD After Revascularization (Duplex/ABI)
Asymptomatic or Stable Symptoms
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
125. ● After angioplasty  stent placement
● Surveillance at 6 to 8 months
U (6)
125. ● After angioplasty  stent placement
● Surveillance at 9 to 12 months or greater
U (6)
126. ● After vein bypass graft
● Surveillance at 3 to 5 months
U (6)
126. ● After vein bypass graft
● Surveillance at 9 to 12 months
U (6)
127. ● After prosthetic bypass graft
● Surveillance at 3 to 5 months
U (5)
127. ● After prosthetic bypass graft
● Surveillance at 9 to 12 months
U (5)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
128. ● After angioplasty  stent placement
● Surveillance every 24 months or greater
U (5)
129. ● After vein bypass graft
● Surveillance every 6 months
U (5)
129. ● After vein bypass graft
● Surveillance every 24 months or greater
U (5)
130. ● After prosthetic bypass graft
● Surveillance every 24 months or greater
U (5)
Lower Extremity Artery Testing With ABI Only
Screening for Lower Extremity Atherosclerotic Disease—Asymptomatic With Comorbidities
134. ● Age 50 years
● With diabetes
U (5)
Lower Extremity Artery Testing with Duplex Ultrasound Only
Evaluation for Groin Complication After Femoral Access
139. ● Ecchymosis U (4)
Upper Extremity Arterial Testing—Physiological Testing or Duplex Ultrasound Study
Evaluation for Upper Extremity PAD—Potential Signs and/or Symptoms
145. ● Raynaud’s phenomenon U (5)
148. ● Discrepancy in arm pulses or blood pressure discrepancy of 20 mm Hg between arms U (6)
149. ● Periclavicular bruit U (5)
Upper Extremity Arterial Testing—Physiological Testing or Duplex Ultrasound Study
Surveillance of Upper Extremity PAD After Revascularization
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
156. ● After vein bypass graft
● Surveillance at 3 to 5 months
U (6)
156. ● After vein bypass graft
● Surveillance at 9 to 12 months
U (5)
157. ● After prosthetic bypass graft
● Surveillance at 6 to 8 months
U (6)
157. ● After prosthetic bypass graft
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Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
158. ● After vein bypass graft
● Surveillance every 6 months
U (4)
158. ● After vein bypass graft
● Surveillance every 24 months or greater
U (5)
159. ● After prosthetic bypass graft
● Surveillance every 6 months
U (4)
159. ● After prosthetic bypass graft
● Surveillance every 24 months or greater
U (4)
*In the setting of interval development of clinical symptoms in a previously asymptomatic patient or for rapid progression of stenosis during subsequent follow-up (e.g., stenosis category change during
a limited period of time), more intensive surveillance may be indicated. †Carotid artery occlusion to be addressed in the text of the document. Periodic surveillance duplex ultrasound should be performed
according to the severity of stenosis of the contralateral side. ‡A screening carotid duplex examination includes assessment for the presence of atherosclerotic plaque within the common and internal
arotid arteries using grey-scale imaging and assessment for stenosis of the proximal internal carotid artery using spectral Doppler. The screening carotid duplex examination is performed using a limited
ut clearly defined screening protocol (see ICAVL 2010 standards 5.1.5 ) (3). A screening study for carotid artery plaque does not include formal measurement of carotid IMT.
ABI  ankle-brachial index; CABG  coronary artery bypass graft; CT  computed tomography; GI  gastrointestinal; ICA  internal carotid artery; IMT  intima-media thickness; PAD  peripheral





Follow-Up or Surveillance for Carotid Artery Stenosis—Asymptomatic
16. ● Normal prior examination (no plaque, no stenosis) I (1)
Surveillance Frequency During First Year
17. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● At 3 to 5 months
I (1)
17. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● At 6 to 8 months
I (1)
17. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● At 9 to 12 months
I (1)
18. ● Mild ICA stenosis (e.g., 50%)
● At 3 to 5 months
I (1)
18. ● Mild ICA stenosis (e.g., 50%)
● At 6 to 8 months
I (1)
18. ● Mild ICA stenosis (e.g., 50%)
● At 9 to 12 months
I (1)
19. ● Moderate ICA stenosis (e.g., 50% to 69%)
● At 3 to 5 months
I (2)
Surveillance Frequency After First Year
21. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● Every 6 months
I (1)
21. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● Every 12 months
I (3)
22. ● Mild ICA stenosis (e.g., 50%)
● Every 6 months
I (2)
23. ● Moderate ICA stenosis (e.g., 50% to 69%)
● Every 6 months
I (3)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
26. ● Following normal ipsilateral ICA baseline study
● Surveillance at 3 to 5 months
I (2)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
28. ● Following normal ipsilateral ICA baseline study
● Surveillance every 6 months
I (2)
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Carotid Duplex Screening Ultrasound
Limited Screening Study for Carotid Artery Plaque—Asymptomatic*
30. ● Low Framingham risk score
● No prior risk assessment imaging study, such as coronary calcium scoring or carotid IMT measurement
I (2)
32. ● Low or intermediate Framingham risk score
● Normal prior risk assessment imaging study, such as coronary calcium scoring or carotid IMT measurement
I (3)
Screening for Renal Artery Stenosis—Asymptomatic
45. ● Atherosclerotic vascular disease in other beds (e.g., peripheral artery disease) and well controlled hypertension I (3)
Evaluation for Mesenteric Artery Stenosis—Potential Signs and/or Symptoms
Symptomatic
47. ● Evaluate for acute abdominal pain ‘out of proportion to exam’
● Leukocytosis, ‘thumbprinting’, pneumatosis or hemoconcentration and acidosis with or without elevated amylase, alkaline
phosphatase or CPK
I (3)
50. ● Chronic constipation or diarrhea
● GI evaluation not yet undertaken
I (3)
Surveillance After Renal or Mesenteric Artery Revascularization
Asymptomatic
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
57. ● During first 12 months after endovascular revascularization
● Surveillance at 3 to 5 months
I (3)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
58. ● After first 12 months after endovascular revascularization
● Surveillance every 6 months
I (3)
Aortic and Aortoiliac Duplex
Evaluation for Abdominal Aortic Disease—Signs and/or Symptoms
60. ● Nonspecific lower extremity discomfort I (3)
66. ● Fever of unknown origin I (3)
67. ● Lower extremity swelling I (2)
71. ● Hypertension I (3)
Screening for Abdominal Aortic Aneurysm—Asymptomatic
81. ● Age 65 years
● No history of smoking
I (3)
Surveillance of Known Abdominal Aortic Aneurysm
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
83. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 3 to 5 months
I (1)
84. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 3 to 5 months
I (1)
Asymptomatic or Stable Symptoms, No or Slow Progression During First Year, Surveillance Frequency After First Year
87. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 6 months
I (2)
88. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 6 months
I (2)
Asymptomatic or Stable Symptoms, Rapid Progression During First Year, Surveillance Frequency After First Year
94. ● Aneurysm 5.5 cm in diameter
● Surveillance every 24 months or greater
I (3)
Surveillance After Aortic Endograft or Aortoiliac Stenting
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
99. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance at 3 to 5 months
I (3)
101. ● Aortic or iliac artery stents
● Surveillance at 3 to 5 months
I (2)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
102. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance every 6 months
I (3)
104. ● Aortic or iliac artery stents
● Surveillance every 6 months
I (2)
I269JACC Vol. 60, No. 3, 2012 Mohler III et al.




Lower Extremity Artery Testing Using Multilevel Physiological Testing Alone or Duplex Ultrasound With Single Level ABI and PVR
Evaluation for Lower Extremity Atherosclerotic Disease—Potential Signs and/or Symptoms
110. ● Nocturnal leg cramps
● Normal pulses
I (2)
111. ● Lack of hair growth on dorsum of foot or toes
● Normal pulses
I (2)
113. ● Lower extremity swelling
● Normal pulses
I (2)
114. ● Diabetes with peripheral neuropathy
● Normal pulses
I (3)
Surveillance of Known Lower Extremity PAD
No Change in Symptom Status (No Revascularization)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
117. ● Normal baseline ABI (no stenosis)
● Surveillance at 3 to 5 months
I (1)
117. ● Normal baseline ABI (no stenosis)
● Surveillance at 6 to 8 months
I (1)
117. ● Normal baseline ABI (no stenosis)
● Surveillance at 9 to 12 months
I (1)
118. ● Mild or moderate disease (e.g., ABI 0.4)
● Surveillance at 3 to 5 months
I (2)
118. ● Mild or moderate disease (e.g., ABI 0.4)
● Surveillance at 6 to 8 months
I (2)
119. ● Severe (e.g., ABI 0.4)
● Surveillance at 3 to 5 months
I (3)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
120. ● Normal baseline ABI (no stenosis)
● Surveillance every 6 months
I (1)
120. ● Normal baseline ABI (no stenosis)
● Surveillance every 12 months
I (1)
120. ● Normal baseline ABI (no stenosis)
● Surveillance every 24 months or greater
I (2)
121. ● Mild or moderate disease (e.g., ABI 0.4)
● Surveillance every 6 months
I (2)
121. ● Mild or moderate disease (e.g., ABI 0.4)
● Surveillance every 12 months
I (2)
122. ● Severe (e.g., ABI 0.4)
● Surveillance every 24 months or greater
I (3)
Surveillance of Lower Extremity PAD After Revascularization (Duplex/ABI)
Asymptomatic or Stable Symptoms
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
125. ● After angioplasty  stent placement
● Surveillance at 3 to 5 months
I (2)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
128. ● After angioplasty  stent placement
● Surveillance every 6 months
I (3)
130. ● After prosthetic bypass graft
● Surveillance every 6 months
I (3)
Upper Extremity Arterial Testing-Physiological Testing or Duplex Ultrasound Study
Surveillance of Upper Extremity PAD After Revascularization
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
157. ● After prosthetic bypass graft
● Surveillance at 3 to 5 months
I (3)
*A screening carotid duplex examination includes assessment for the presence of atherosclerotic plaque within the common and internal carotid arteries using grey-scale imaging and assessment for
stenosis of the proximal internal carotid artery using spectral Doppler. The screening carotid duplex examination is performed using a limited but clearly defined screening protocol (see ICAVL 2010
standards 5.1.5) (3). A screening study for carotid artery plaque does not include formal measurement of carotid IMT.ABI  ankle-brachial index; CABG  coronary artery bypass graft; CPK  creatine phosphokinase; GI  gastrointestinal; I  inappropriate; ICA  internal carotid artery; IMT  intima-media thickness;
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The noninvasive vascular laboratory plays a central role in
the evaluation and surveillance of peripheral vascular disor-
ders. The scope of this document includes common clinical
indications encountered in patients with suspected or
known non-coronary arterial disorders, including athero-
sclerotic occlusive disease (i.e., carotid artery stenosis, lower
nd upper extremity peripheral arterial disease, renal and
esenteric artery occlusive disease), abdominal aortic aneu-
ysms, and also less common disorders such as fibromuscular
ysplasia, vasospasm, arterial dissection, and arterial trauma.
valuation of the thoracic aorta is not generally undertaken in
he noninvasive vascular laboratory and is beyond the scope of
his document. The appropriate use of transthoracic echocar-
iography for evaluation of aortic disease is addressed in the
011 Appropriate Use Criteria for Echocardiography (16).
Due to the diversity of peripheral vascular disorders, it is
likely that many potential clinical indications are not in-
cluded in this document. Rather than an exhaustive com-
pendium of clinical indications, it is intended that this
document address the most common and important clinical
scenarios encountered in the care patients with peripheral
vascular disease. This document includes ratings for both
duplex ultrasound examinations and physiological testing
studies (when appropriate). This document includes indi-
cations related to arterial disorders only; separate appropri-
ateness criteria for venous ultrasound and physiological
testing, which will also include indications related to dialysis
access, are under development and anticipated in the near
future. It is intended that this document will provide
guidance for clinicians in maximizing the appropriate use of
the noninvasive vascular laboratory for the care of patients
with suspected or known peripheral vascular disorders. In
addition, it is intended that this document identify critical
evidence gaps in the field and serve as a reference for policy
makers with regard to noninvasive vascular testing.
Appropriate Use Criteria were developed using medical
evidence and supplemented by expert opinion to assess
whether the net benefit or risks of a noninvasive, vascular
laboratory–based, diagnostic test for arterial disease make it
reasonable to perform. The intent of the criteria is to avoid
over- or underutilization, thereby promoting optimal health-
care delivery along with justifying healthcare expenditures and
promoting the best outcome for patients with minimal risk.
The AUC for vascular laboratory testing were developed
as complimentary and are aligned with the ACC/AHA
Guidelines for the Management of Patients with Peripheral
Arterial Disease and the ASA/ACC/AHA multisocietal
Guidelines for the Management of Patients with Extracra-
nial Carotid and Vertebral Artery disease (7,14). Specifi-
cally, the ACC/AHA PAD and carotid/vertebral guidelines
include, for each vascular territory, a section on diagnostic
methods. The current AUC document includes some of the
diagnostic methods for disease investigation such as ultrasoundand physiological testing. Other modalities such as computed
tomography and magnetic resonance are not covered in the
current AUC document.
It should be noted that the optimal clinical management
of many common peripheral vascular disorders requires
periodic imaging surveillance, both to follow for disease
progression and to determine the time at which a threshold
for intervention has been reached. In contrast to many
cardiac conditions, peripheral arterial interventions are often
indicated to prevent untoward vascular events in the patient
with severe but asymptomatic vascular disease. Examples of
such indications include repair of a large but asymptomatic
abdominal aortic aneurysm to prevent fatal rupture or
revascularization of severe asymptomatic internal carotid
artery stenosis to prevent ipsilateral stroke. As such, there
are many more surveillance indications included in the
current AUC document than in the AUC for other cardio-
vascular imaging modalities, such as echocardiography or
nuclear imaging. In addition, it must be noted that periodic
noninvasive vascular testing is a standard component of care
following vascular intervention, such as follow-up of a lower
extremity bypass graft or arterial stent for significant steno-
sis or for assessment after endovascular aortic aneurysm
repair to assure aneurysm exclusion and the absence of
endoleak. In some clinical settings, repeat intervention may
be required based solely upon surveillance ultrasound find-
ings in the absence of worsening clinical symptoms, such as
to optimize primary assisted patency of a severely stenotic
lower extremity bypass graft.
Summary of Evidence
and Call for Additional Research
A consensus of “appropriate” was found for most vascular
studies where clinical signs and symptoms were the indica-
tion for testing and to establish a “baseline” after a revascu-
larization procedure. In general, a follow-up study for a
patient with a normal baseline study was deemed inappropri-
ate. For cerebrovascular disease, a duplex ultrasound study was
appropriate for hemispheric neurological symptoms such as
transient ischemic attack or stroke. There was uncertainty
regarding the use of cerebrovascular ultrasound for assessment
of asymptomatic patients with risk factors or comorbidities for
carotid artery stenosis, but this was deemed appropriate for
assessment of occult cerebrovascular disease in patients with
established atherosclerotic disease in other vascular territories.
Another area considered uncertain for cerebrovascular ultra-
sound was preoperative assessment prior to cardiac surgery.
For duplex ultrasound to assess for renal artery stenosis,
appropriate testing indications were hypertension, increased
creatinine, and heart failure and for mesenteric artery
stenosis were patients with postprandial pain and weight
loss who have previously undergone GI evaluation. The
appropriate indications for evaluation of the abdominal
aorta and iliac arteries included intermittent claudication, an
aneurysmal femoral or popliteal pulse, a pulsatile abdominal
mass, a decreased or absent femoral pulse, and an abdominal
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in the lower extremities, abnormal physiological testing
suggestive of aortoiliac occlusive disease, and the presence of
a thoracic aortic aneurysm. Erectile dysfunction was con-
sidered an uncertain indication of duplex ultrasound of the
aorta and iliac arteries. Inappropriate indications for aorta
and iliac duplex ultrasound were nonspecific discomfort and
swelling in lower extremities, fever of unknown origin, and
hypertension. Surveillance of known aortic or iliac aneu-
rysms was appropriate but did depend on size of the vessel
and rapidity of enlargement.
Lower or upper extremity physiological testing alone or
duplex ultrasound with single-level ABI and PVR was
appropriate for signs and symptoms of ischemia. Screening
tests for the various vascular territories were appropriate for
abdominal aortic aneurysms and the ratings were generally
consistent with USPSTF recommendations. The screening
of selected populations with the ABI was uncertain and
reflects the paucity of data regarding effect on prevention of
claudication and limb loss. However, it did not address
whether ABI screening would impact the high rate of heart
attack and stroke in patients with PAD. With regard to
carotid artery ultrasound screening, a low Framingham risk
score was an inappropriate indication, whereas an interme-
diate or high Framingham risk score was an uncertain
indication. The uncertain indications noted in all the
vascular territories exposes the need for outcome and clinical
effectiveness data to allow for appropriateness certainly.
The current evidence base and clinical practice guidelines
were used to develop and rate the clinical indications
whenever available, although for certain indications, the
available scientific literature was limited and clinical exper-
tise played a larger role. The writing panel recognizes a need
for more clinical and cost-effectiveness studies focused
specifically on noninvasive vascular testing, and the signif-
icant number of indications rated by the technical panel as
“uncertain” are reflective of these evidence gaps. The writing
panel identifies the following areas as among those in
greatest need of focused research:
1. Clinical and cost effectiveness of carotid artery duplex
examinations prior to open heart surgery.
2. Cost–benefit analysis and utility of carotid duplex ultra-
sound examination for asymptomatic patients with ath-
erosclerotic vascular disease in other vascular beds (e.g.,
coronary or peripheral artery disease) and for patients
with multiple atherosclerotic risk factors.
3. Optimal frequency of ultrasound examinations for surveil-
lance of untreated internal carotid artery stenosis, accounting
for severity of disease on the baseline examination.
4. Optimal frequency of ultrasound examinations for sur-
veillance of abdominal aortic aneurysms, accounting for
size of the aneurysm on the baseline examination and
select patient characteristics (e.g., gender).
5. Optimal frequency of ultrasound and physiological test-
ing for surveillance following lower extremity arterialbypass grafts and endovascular revascularization proce-
dures, accounting for type of procedure (stenting or
bypass), nature of conduit (for bypass grafting), and
anatomic location of the procedure.
6. Comparative effectiveness of duplex ultrasound versus other
imaging modalities for surveillance after aortic endografting.
Appendix A: Additional Methods
See the Methods section of the report for a description of
panel selection, indication development, scope of indica-
tions, and rating process.
Relationships With Industry and Other Entities
The College and its partnering organizations rigorously
avoid any actual, perceived, or potential conflicts of interest
that might arise as a result of an outside relationship or
personal interest of a member of the technical panel.
Specifically, all panelists are asked to provide disclosure state-
ments of all relationships that might be perceived as real or
potential conflicts of interest. These statements were reviewed
by the Appropriate Use Criteria Task Force, discussed with all
members of the technical panel at the face-to-face meeting,
and updated and reviewed as necessary. A table of disclosures
by the technical panel and oversight working group members
can be found in Appendix C.
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